International Journal of Pharmacology and Clinical Research (IJPCR)

An Observational Study Of Etiology And Clinical Manifestations Of Anaemia In Rural Hospital

Yadavendra Reddy Chama, Karunakar — Tue, 12 Jul 2022 00:00:00 +0000

Anemia is very commonly encountered in general clinical practice among all age groups. Although the etiology for such is truly myriad, with a comprehensive history, physical examination, and directed laboratory evaluation, a specific diagnosis can often be arrived at. A comprehensive history, physical examination, and directed laboratory evaluation will help to identify a specific cause for anemia. So, the present study was conducted for clinical and laboratory evaluation of anemia in local population and to find out its etiology for appropriate treatment and preventive strategies.

Methods: The present study was done over one year in a rural hospital. All patients who were anaemic during the study period were enrolled.patients below 18 years,who did not give consent for the study were excluded. Complete detailed history was taken and general physical examination is done for all patients.

Results:out of 230 patients there was female preponderance with 163 females and 37 males.there were more number of patients in age group 21-30 yrs about 59.among the symptoms fatigue was followed by shortness of breath and weight loss.

Conclusion: The mean age of the study patients was 44.86 ± 15.7 with age range of 21 – 74 years and the gender ratio female: male of the study was 2.43:1. Fatigue or generalized weakness was the most common symptoms

Keywords:anaemia,fatigue,sob,weakness,microcytic

Effect of obesity on PCOD (polycystic ovarian disorder)

Tue, 26 Jul 2022 14:43:44 +0000

While many women with polycystic ovary syndrome (PCOS) are overweight, obese or centrally obese, the effect of excess weight on the outcomes of PCOS is inconsistent. The review aimed to assess the effects of overweight, obesity and central obesity on the reproductive, metabolic and psychological features of PCOS. MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL) and PSYCINFO were searched for studies reporting outcomes according to body mass index categories or body fat distribution. Data were presented as mean difference or risk ratio (95% confidence interval). This review included 30 eligible studies. Overweight or obese women with PCOS had decreased sex hormone-binding globulin (SHBG), increased total testosterone, free androgen index, hirsutism, fasting glucose, fasting insulin, homeostatic model assessment-insulin resistance index and worsened lipid profile. Obesity significantly worsened all metabolic and reproductive outcomes measured except for hirsutism when compared to normal weight women with PCOS. Overweight women had no differences in total testosterone, hirsutism, total-cholesterol and low-density lipoprotein-cholesterol compared to normal weight women and no differences in SHBG and total testosterone compared to obese women. Central obesity was associated with higher fasting insulin levels. These results suggest that prevention and treatment of obesity is important for the management of PCOS^.

Review on current scenario of dengue vaccine

Mohd Wasiullah, Syed Yasoob Zaidi, Yusuf Quraishee, Shashikant Maury — Tue, 26 Jul 2022 14:58:30 +0000

Dengue fever is the most prevalent arboviral disease, caused by one of four separate but closely related dengue viruses (DENV), and it has a considerable economic and public health impact in endemic areas. A dengue vaccine will be critical in furthering illness management. However, the work has been hampered by the need to induce good protection against all four DENV serotypes, as well as the possibility of an unfavourable effect due to the phenomena that partial immunity to DENV may aggravate symptoms upon future heterotypic infection. The most modern dengue vaccines available today are all tetravalent and based on recombinant live attenuated viruses. Sanofi Pasteur's CYD-TDV vaccine has been licenced for use in people who have previously been infected with dengue. Two other tetravalent live attenuated vaccine candidates: TAK-003 by Takeda and TV003 by National Institute of Allergy and Infectious Diseases, have completed phase 3 and phase 2 clinical trials, respectively.